PRAX · US market
Praxis Precision Medicines Inc
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$8.01bnFinancials dated 30 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- -US$339.13m
- Latest-quarter run-rate earnings
- -US$334.88m
- Latest fiscal-year earnings
- -US$303.27m
- Trailing revenue
- US$0.00
- Latest-quarter run-rate revenue
- US$0.00
- Latest fiscal-year revenue
- Unavailable
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- IBRN · iShares Neuroscience and Healthcare ETF5.49% weight · Holdings dated 21 August 2026
- GNOM · Global X Genomics & Biotechnology ETF3.89% weight · Holdings dated 31 May 2026
- XBI · State Street SPDR S&P Biotech ETF1.41% weight · Holdings dated 21 August 2026
- MMSC · First Trust Multi-Manager Small Cap Opportunities ETF1.04% weight · Holdings dated 31 May 2026
- HELX · Franklin Genomic Advancements ETF0.86% weight · Holdings dated 30 June 2026
- IBB · iShares Biotechnology ETF0.69% weight · Holdings dated 19 August 2026
- DLBMX · MassMutual Small Cap Opportunities Fund Class A0.65% weight · Holdings dated 30 June 2026
- BRSDX · MFS Blended Research Small Cap Equity Fund Class A0.64% weight · Holdings dated 31 May 2026
- IWO · iShares Russell 2000 Growth ETF0.59% weight · Holdings dated 19 August 2026
- BUFSX · Buffalo Small Cap Growth Fund0.58% weight · Holdings dated 30 June 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 30 June 2026. Informational research, not investment advice.